MD edge: PRESERVED-HF: Dapagliflozin improves physical limitations in patients with HFpEF

September 14, 2021

The SGLT2 inhibitor dapagliflozin scored a clear win in a randomized, controlled trial with more than 300 U.S. patients with heart failure with preserved ejection fraction (HFpEF), showing a significant and clinically meaningful benefit for the primary endpoint, a KCCQ measure of symptoms and physical limitations, after 12 weeks of treatment.

In the PRESERVED-HF study, patients with HFpEF who received a standard, once-daily dose of dapagliflozin (Farxiga) had an average 5.8-point improvement in their condition as measured by the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CS), the study’s primary endpoint.

Read the full MD edge article: PRESERVED-HF: Dapagliflozin improves physical limitations in patients with HFpEF

Related Content

Saint Luke's Mid America Heart Institute
PRESERVED-HF trial findings on the substantial impact of dapagliflozin in individuals with heart failure with preserved ejection fraction (HFpEF) published in Nature Medicine
The findings of the PRESERVED-HF trial, offering potential new hope for people struggling with heart failure with preserved ejection fraction (HFpEF), are published in the journal, Nature Medicine.
Medpage Today: SGLT2 Inhibitor Eases Symptoms for HFpEF Patients
Symptoms of heart failure with preserved ejection fraction (HFpEF) improved with dapagliflozin (Farxiga) therapy, the PRESERVED-HF trial showed.